Navigation Links
GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
Date:1/13/2009

TORONTO, Jan. 13 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced it has been granted U.S. Patent # 7,473,528 entitled "Method for the detection of Chagas disease related gene transcripts in blood". This patent protects the Company's discovery of a blood biomarker-based method of testing for Chagas disease, a serious and potentially fatal disease resulting from parasitic infection. Chagas disease is a significant public health issue affecting more than 11 million people worldwide each year.

"The Sentinel Principle(TM) technology is the basis of not only this issued patent but also for the personalized health management system we are developing which applies genomic information to monitor and address health concerns on an individualized basis," stated Dr. Choong-Chin Liew, the discoverer of the Sentinel Principle and Co-founder, Chief Scientist and Director of GeneNews. "GeneNews has a broad array of pending patent applications in diverse disease areas including oncology, cardiovascular, neurological and inflammatory conditions," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "This is our first patent issuance based on our Sentinel Principle platform technology and represents an important initial milestone to realize commercial value from our pipeline of discoveries." The Company currently has five issued patents and more than 70 pending patent applications, the majority of which are based on the application of the Sentinel Principle.

    About GeneNews
    ---------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews Announces First Quarter Results
9. Genenews adds two members to its Board of Directors
10. GeneNews announces management changes to support commercialization of ColonSentry(TM)
11. GeneNews launches worlds first blood test for colorectal cancer screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... talent development and compliance training, today announced an interactive FDA compliance training ... The RAPS (Regulatory Affairs Professional Society) accredited interactive course on Morf Playbook—now ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today provided an ... in the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings ... Office.  The IPR was initiated on only certain claims ...
(Date:2/3/2016)... , Feb. 3, 2016   ViaCyte, Inc ... the first pluripotent stem cell-derived islet replacement therapy ... clinical-stage development, today announced that ViaCyte and Janssen ... of Johnson & Johnson, have agreed to consolidate ... ViaCyte.  The agreement provides ViaCyte with an exclusive ...
Breaking Biology Technology:
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
(Date:1/11/2016)... 11, 2016 Synaptics Incorporated (NASDAQ: SYNA ... announced that its ClearPad ® TouchView ™ ... two separate categories in the 8 th Annual ... Technology Breakthrough. The Synaptics ® TDDI solution enables ... chain, thinner devices, brighter displays and borderless designs. ...
(Date:1/8/2016)... NXTD ), a company focused ... a privately held leading direct seller of vacation and ... fastest-growing company announced that on December 31, 2015, that ... Nxt-ID to develop a proprietary new wireless smart card ... a unique smart wallet that serves to securely store ...
Breaking Biology News(10 mins):